These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31463367)

  • 1. Coxsackievirus Type B3 Is a Potent Oncolytic Virus against
    Deng H; Liu H; de Silva T; Xue Y; Mohamud Y; Ng CS; Qu J; Zhang J; Jia WWG; Lockwood WW; Luo H
    Mol Ther Oncolytics; 2019 Sep; 14():266-278. PubMed ID: 31463367
    [No Abstract]   [Full Text] [Related]  

  • 2. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
    Liu H; Xue YC; Deng H; Mohamud Y; Ng CS; Chu A; Lim CJ; Lockwood WW; Jia WWG; Luo H
    Mol Ther Oncolytics; 2020 Mar; 16():207-218. PubMed ID: 32123721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
    Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
    Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oncolytic coxsackievirus therapy as an immunostimulator].
    Miyamoto S; Sagara M; Kohara H; Tani K
    Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer.
    Cai L; Liu Z
    Cancer Med; 2020 Jul; 9(14):5210-5220. PubMed ID: 32459400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis.
    Zhang Y; Xu T; Tian H; Wu J; Yu X; Zeng L; Liu F; Liu Q; Huang X
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3.
    Liu H; Bahreyni A; Mohamud Y; Xue YC; Jia WWG; Luo H
    Mol Ther Oncolytics; 2022 Dec; 27():89-99. PubMed ID: 36321136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Bahreyni A; Liu H; Mohamud Y; Xue YC; Zhang J; Luo H
    Cancer Lett; 2022 Nov; 548():215849. PubMed ID: 35995138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway.
    Luo H; Yanagawa B; Zhang J; Luo Z; Zhang M; Esfandiarei M; Carthy C; Wilson JE; Yang D; McManus BM
    J Virol; 2002 Apr; 76(7):3365-73. PubMed ID: 11884562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Ambrogio C; Barbacid M; Santamaría D
    Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
    Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
    Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
    J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3.
    Jia Y; Miyamoto S; Soda Y; Takishima Y; Sagara M; Liao J; Hirose L; Hijikata Y; Miura Y; Hara K; Iwanaga A; Ota Y; Tani K
    Mol Ther Oncolytics; 2019 Mar; 12():246-258. PubMed ID: 30891489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM21 Restricts Coxsackievirus B3 Replication, Cardiac and Pancreatic Injury via Interacting With MAVS and Positively Regulating IRF3-Mediated Type-I Interferon Production.
    Liu H; Li M; Song Y; Xu W
    Front Immunol; 2018; 9():2479. PubMed ID: 30410495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
    Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
    J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
    Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
    Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
    Chaft JE; Litvak A; Arcila ME; Patel P; D'Angelo SP; Krug LM; Rusch V; Mattson A; Coeshott C; Park B; Apelian DM; Kris MG; Azzoli CG
    Clin Lung Cancer; 2014 Nov; 15(6):405-10. PubMed ID: 25044103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.